A new study published in Diabetes Care sheds light on the comparative risks of peripheral artery disease (PAD)-related surgical events—such as amputations, stent placements, or vascular surgeries—between two classes of diabetes medications: sodium-glucose cotransporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase 4 inhibitors (DPP-4i). Conducted among U.S. veterans, this retrospective cohort study analyzed over 150,000 episodes of medication... Continue Reading →